CRISM Therapeutics Corporation reverse takeover of Extruded Pharmaceuticals Limited

The transaction was valued at £5.5 million and was settled through the issuance of 23,939,986 new ordinary shares in CRISM Therapeutics Corporation, formerly known as Amur Minerals Corporation.

CRISM Therapeutics Corporation, is a pioneering entity in drug delivery technology specialising in targeted cancer treatments. This strategic acquisition marks CRISM’s transition from mineral exploration to a focus on pharmaceutical advancements. CRISM’s successful listing on AIM underlines its commitment to advancing cancer treatment technologies and its readiness to embark on the next phase of clinical development.

Ian Cliffe, Partner, said: “We are delighted to have supported CRISM on this acquisition. This deal represents a significant milestone for the company, and we are proud to have played a role in facilitating their strategic transition into the pharmaceutical sector. Our team is confident that CRISM’s innovative approach to cancer treatment will yield substantial benefits for patients and stakeholders alike.”

The haysmacintyre team included Ian Cliffe, Partner, James Gramston, Director, Sophie Knight, Manager, and Philippa Taylor and Shannon Goodwin, Assistant Managers.